Pipeline Therapeutics to Participate in the 2020 RBC Capital Markets and SVB Leerink Private Company Conferences




Pipeline Therapeutics to Participate in the 2020 RBC Capital Markets and SVB Leerink Private Company Conferences

SAN DIEGO–(BUSINESS WIRE)–Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the company will participate in two upcoming investor conferences in December.

2020 RBC Capital Markets Healthcare Private Company Conference

Format: Analyst-Led Fireside Chat

Date: Tuesday, December 15, 2020

Time: 9:20 a.m. ET / 6:20 a.m. PT

SVB Leerink Biopharma Private Company Connect

Format: One-on-one meetings

Date: December 15-17, 2020

About Pipeline Therapeutics

Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair. The company’s lead clinical program, PIPE-505, is currently enrolling patients in a phase 1/2a study to treat sensorineural hearing loss (SNHL) associated with speech-in-noise disability. The company also has a portfolio of programs addressing a range of neurological disorders, including development candidate PIPE-307 which is focused on remyelination to treat multiple sclerosis. For more information, please visit www.pipelinetherapeutics.com.

Contacts

Company Contact:
Carmine Stengone

President and CEO

info@pipelinetherapeutics.com

Investor Contact:
Laurence Watts

619-916-7620

laurence@gilmartinir.com